VREOF (Vireo Growth) Cash And Cash Equivalents : $86.26 Mil (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Vireo Growth Cash And Cash Equivalents?

Vireo Growth's quarterly cash and cash equivalents increased from Sep. 2024 ($7.28 Mil) to Dec. 2024 ($91.61 Mil) but then stayed the same from Dec. 2024 ($91.61 Mil) to Mar. 2025 ($86.26 Mil).

Vireo Growth's annual cash and cash equivalents increased from Dec. 2022 ($15.15 Mil) to Dec. 2023 ($15.97 Mil) and increased from Dec. 2023 ($15.97 Mil) to Dec. 2024 ($91.61 Mil).

Vireo Growth Cash And Cash Equivalents Historical Data

The historical data trend for Vireo Growth's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vireo Growth Cash And Cash Equivalents Chart

Vireo Growth Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

25.51

15.16

15.15

15.97

91.61

Vireo Growth Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash And Cash Equivalents	Get a 7-Day Free Trial															12.60	11.23	7.28	91.61	86.26

Vireo Growth Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Vireo Growth (OTCPK:VREOF) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Vireo Growth Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Vireo Growth's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Vireo Growth Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vireo Growth Inc (OTCPK:VREOF) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

0ZF:Germany VREO:Canada

Address

207 South 9th Street, Minneapolis, Minneapolis, MN, USA, 55402

Website

https://www.vireogrowth.com

Vireo Growth Inc is a cannabis company whose mission is to provide safe access, quality products, and value to its customers while supporting its local communities through active participation and restorative justice programs. The company's operating results in one business segment: the cultivation, production, and sale of cannabis.

Executives

Chicago Atlantic Credit Opportunities, Llc	10 percent owner	420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Manager, Llc	10 percent owner	420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Gp Holdings, Llc	10 percent owner	420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Group, Lp	10 percent owner	420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Group Gp, Llc	10 percent owner	420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Advisers, Llc	10 percent owner	420 NORTH WABASH AVENUE, SUITE 500, CHICAGO IL 60611
Joshua Rosen	director	207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Victor E. Mancebo	director	C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Christian Gonzales Ocasio	officer: Chief Operating Officer	C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Amber Holly Shimpa	director, officer: Chief Administrative Officer	C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Patrick Peters	officer: EVP of Retail	C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
J Michael Schroeder	officer: General Counsel & CCO	3680 VICTORA STREET N, SHOREVIEW MN 55126
John Andrew Heller	officer: Chief Financial Officer	C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Ross Michael Hussey	director	C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Judd Theodore Nordquist	director	C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402